Moneylife » Life » Public Interest » GlaxoSmithKline’s crooked behaviour: Norm or exception?
GlaxoSmithKline’s crooked behaviour: Norm or exception?
GlaxoSmithKline has pleaded guilty to criminal charges, and agreed to pay $3 billion in fines for various sins. Well, GSK is not alone. GSK has been caught doing what all pharma companies do most of the time, as I have been warning for decades
“Power corrupts. Knowledge is power. Study hard. Be evil.”— Anon
This seems to be the hot news in the US today. But for me this is no news at all. This happens with all companies and all drugs all the time. I have been warning people about this for decades. I feel happy today that many of my detractors will feel bad that a governmental agency has been able to spot this fraud! Read the news as it is below:
Washington—Global healthcare giant GlaxoSmithKline LLC (GSK) agreed to plead guilty and to pay $3 billion to resolve its criminal and civil liability arising from the company’s unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices, the Justice Department announced today. The resolution is the largest health care fraud settlement in US history and the largest payment ever by a drug company.
GSK agreed to plead guilty to a three-count criminal information, including two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce; and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration (FDA). Under the terms of the plea agreement, GSK will pay a total of $1 billion, including a criminal fine of $956,814,400 and forfeiture in the amount of $43,185,600. The criminal plea agreement also includes certain non-monetary compliance commitments and certifications by GSK’s US president and board of directors. GSK’s guilty plea and sentence is not final until accepted by the US district court.
What makes this interesting are the revelations further of what GSK has been doing which again is what all companies do but, let us see it from the source.
“GSK paid a speaker to talk to an audience of doctors and paid for the meal or spa treatment for the doctors who attended.”
“The United States contends that GSK paid millions of dollars to doctors to speak at and attend meetings, sometimes at lavish resorts, at which the off-label uses of Wellbutrin were routinely promoted and also used sales representatives, sham advisory boards, and supposedly independent Continuing Medical Education (CME) programs to promote Wllbutrin for these unapproved uses.”
In the past I had written about a good book “The truth about drug companies—How they deceive the public and what to do about it” by the former editor of the prestigious New England Journal of Medicine, Marcia Angell. She was the editor for 20 years and before that her husband, Relman, was there for 20 years. Both of them are now fighting the drug company menace in the USA. This book will let the reader have all the inside dealings of the drug lobby to sell their wares even when they know that the drugs that they were going to launch could kill many people. They do not want their share holders to lose their money. Here is one case in the open now. GSK was fully aware that the glitazone that they were going to release to the market could result in heart attacks in the recipient but they wanted to make enough money before that comes out in the open. Obviously, for them patient deaths were just statistics but their profit was sacrosanct!
The said company was well aware of the dangers of administering anti-depressants to children below the age of 18. They not only used dubious methods to promote the drug for depression in those below 18 years of age but they invented new indications like attention disorder, etc in children to sell the drugs. Antidepressants in children could increase their suicidal tendency! In her beautiful book “Dementia—a crime against mankind” by Elizabeth Grace Jackson, a professor of psychiatry in the US Navy, she gives us the dangers of antidepressants in general and shows how the epidemic of dementia these days is due to abuse and overuse of psychiatric drugs!
The other big criminal act by the drug companies is to sponsor the so called Continued Medical Education (CME) for doctors. It should instead be called “Continuing Brain washing of Doctors” by drug companies (CBD). The scenario is the same in India. Of course, we ape the Americans in every sphere of human activity, more so in medicine. You have now realized what the receptionist means when she tells you to come after the doctor has returned from the conference. John Ioannidis MD, DSc from Stanford University is an expert in finding the loopholes in our medical system. His recent paper “Are medical Conferences useful?” in the prestigious JAMA (JAMA. 2012;307:1257-1258) gives the following facts about conferences, which I call as CBDs.
“Do medical conferences serve any purpose? In theory, these meetings aim to disseminate and advance research, train, educate, and set evidence-based policy. Although these are worthy goals, there is virtually no evidence supporting the utility of most conferences. Conversely, some accumulating evidence suggests that medical congresses may serve a specific system of questionable values that may be harmful to medicine and health care. Power and influence appear plentiful in many of these meetings. Not surprisingly, the drug, device, biotechnology, and health care–related industries make full use of such opportunities to engage thousands of practicing physicians. Lush exhibitions and infiltration of the scientific program through satellite meetings or even core sessions are common avenues of engagement. Although many meetings require all speakers to disclose all potential conflicts, the majority of speakers often have numerous conflicts, as is also demonstrated in empirical evaluations of similar groups of experts named on authorship lists of influential professional society guidelines.”
“Meetings may also create a branding system that builds the reputations of scientists working in the field and promotes herding after elevated prestigious opinion leaders. Opinion leaders are experts whose valued utterances can exercise wide influence regardless of, in the absence of, or even against evidence. Gaining the podium for the plenary presentation or important sessions at a major meeting confers prestige, even though there is little safeguard that what these featured speakers say has any value and quality. Each professional society and organization creates its cadre of leaders, with meetings making these leaders visible to the members who usually participate passively by listening. Given the dynamics of large professional societies and conferences, leadership is sometimes judged not on scientific merit, hard work, and originality of thought but rather on the ability to navigate power circles. Some young scientists may be even discouraged to think that merit, hard work, and originality of thought is what counts. Instead, they may struggle to become better positioned within influential societies, with the hope that they will some day gain a spot on the podium of the specialty arena.”
One of my friends, an industrialist, had recently gone to Singapore for a cruise. To his wife’s surprise 98% of the passengers were Indian. She was very proud of our country to know how rich our people were. Next morning during breakfast she had a group of ladies talking to her. She found out that all of them in the ship were from one city in India and they were all doctors and their spouses! The cruise was booked by one drug company in return for the favours done! My friend’s wife had a shock of her life. She has not been seeing doctors for minor complaints ever since!
Instrument companies do not lag behind either. For each cardiac stent inserted for example the company budgets a small amount of $500 as doctors’ hospitality. The manufacturing cost is just about $10. The company might make a small profit of just $1490 or so per stent! This assessment of mine might be subject to revision recently! All that glitters is not gold in the field of human healing. Are you now happy that medical arena is one big business where profit is the ONLY motto irrespective of consequences based on the corporate principle of Bernard Mandeville, Adam Smith’s teacher. Long live mankind on tender loving care of good humane doctors who have not fallen prey to this yet. They have lots of temptations. I am happy to let you know that there are many such good souls who are not hard to find if you look carefully even today.
“Yes! Finally captured Martha Stewart. You know, with all the massive and almost completely unpunished fraud perpetrated on the American public by such companies as Enron, Global Crossing, Tyco and Adelphia, we finally got the ringleader. Maybe now we can lower the nation's terror alert to periwinkle.”— Jon Stewart.
(Professor Dr BM Hegde, a Padma Bhushan awardee in 2010, is an MD, PhD, FRCP (London, Edinburgh, Glasgow & Dublin), FACC and FAMS. He is also editor-in-chief of the Journal of the Science of Healing Outcomes, chairman of the State Health Society’s Expert Committee, Govt of Bihar, Patna. He is former vice-chancellor of Manipal University at Mangalore and former professor for cardiology of the Middlesex Hospital Medical School, University of London. Prof Dr Hegde can be contacted at hegdebm@gmail.com)
More in Moneylife
PNB Metlife refunds Rs25,000 to the correct policyholder: another Moneylife victory +3390 views
TODAY'S TOP STORIES
Post your Comment
| Alert me when new comment is posted on this article | |
| Please read our Moderation Policy and Terms of Use before posting | |
VIDEOS
Keep your Money Safe: Avoid money traps and MLM
LATEST COMMENT
MORE
VVIP cremation: Some birds are more equal...
Mass mis-selling: 59,000 investors in Kolhapur are alleged to have lost money in LIC ULIPs
|
|
|
|||||||||||||||||||||||
|
Take advantage of all our features and functionality exclusively designed for Moneylife.in members. Registration gives you easy access to - Moneylife Newsletters - Exclusive News - Special Features - Membership to Moneylife Foundation - Other Value adds And the registration to this website is completely free. Go ahead and submit this form to create your new profile. |
Tell us about yourself
I have read and agreed to the Terms & Conditions | |||||||||||||||||||
- Is the interest in Gold ETFs waning?
- Do FIIs buy high and sell low – I? Maximum buying at peak index levels
- OMCs to stop LPG deliveries to houses with multiple-connections from 1st June
- COMPAT orders cement cos to pay 10% of the Rs6,307 crore penalty
- Sun TV Networks announces 11% jump in its net profit
- BSE to shift 29 scrips to T group category for failure to comply with demat norms
- S&P cautions India of rating downgrade; retains negative outlook
- ITC net profit up 19.4%, aided by non-cigarette and agri-business segments
- Vikram Pandit to buy stake in JM Financial, to head its proposed banking arm
- MMM India, another MLM taking people for “double-your-money” ride
- RBI tells HDFC Bank not to make up its own KYC verification rules
- Why I-T returns of Pawar, Jindal and Gandhi are exempted from RTI?
- The draconian LBT: Local Body Tax explained
- How much longer can the FM, RBI ignore HSBC in India?
- Aadhaar: Private ownership of UID data- Part I
- Aadhaar: Who owns the UID database? –Part II
- Did HSBC Bank resort to toxic churning and illegitimate transactions to earn commissions?
- PNB Metlife refunds Rs25,000 to the correct policyholder: another Moneylife victory
- The draconian LBT: Local Body Tax explained
- Goa’s Advocate General is the highest paid across the country, reveals RTI
- Mass mis-selling: 59,000 investors in Kolhapur are alleged to have lost money in LIC ULIPs
- Do FIIs buy high and sell low – I? Maximum buying at peak index levels
- Investors lost Rs1 lakh crore due to poor regulation. Will there be a CBI probe?
- High Mark to sell 250 million records to another credit bureau?
- Directors of public sector banks: The ground reality
- System glitch deducts 40% amount as TDS from SBI depositors’ account!
- Do FIIs buy high and sell low–II? Momentum-chasing
What's your say?
| Yes | |||||||
| No | |||||||
| Can't Say | |||||||
|
What you said
Thanks for casting your votes! View Previous Polls
Join 22, 000 Others
Membership Benefits
- Daily & Weekly newsletters
- Access to www.moneylife.in to comment, create alerts
- Your own profile in Moneylife.in
- All special mailers
- Basic membership to MSSN, our new initiative
- Free ebooks
- Invitation to events
- Invitation to round-table meets
- Access to Insurance helpline
- Access to counselling sessions
- Access to Reading room in Mumbai
| Name: |
|
| Email: |
|
| Phone: |
|
| Catagory | |
| Message: |
|
| Enter Code: |
|






























Comment
Narain Jagirdar 11 months ago
Almost all pharma companies across the world are perhaps guilty of such practices, for they go under the name of marketing.The US is the mother country for birth of these practices and if one company is pulled up, it doesn't mean rule of law works there...this is an exception. The Pharmaceutical Manufacturers Association in the US is an extremely strong and a rich lobby. A similar practice in the case of another company might have got regularized of which we are not aware.
Adi Daruwalla 11 months ago
Education corrupts and business education corrupts absolutely !!
P M Ravindran 11 months ago
That's the difference between actual rule of law in an actual democracy in US and the farce being perpetrated in a fraud democracy in India in the name of rule of law!